Grindeks is a pharmaceutical company based in Latvia that develops, manufactures, and markets a range of medicinal products and active pharmaceutical ingredients. The company specializes in several key therapeutic areas, including cardiovascular diseases, disorders of the central nervous system, oncology, and infectious diseases. It operates manufacturing sites in Riga and focuses on both original branded products and generic medicines to serve markets in Europe and beyond.
The company has a history dating back to the mid-20th century and has evolved into a vertically integrated organization with capabilities in research, production, and distribution. Grindeks is listed on the stock exchange in Riga and maintains compliance with international quality standards such as those set by the European Medicines Agency. Its products are authorized in multiple countries, as evidenced by references in regulatory reviews like the one conducted by the EMA on ipidacrine-containing medicines.
In addition to finished dosage forms, Grindeks produces active ingredients that are used internally and supplied to other pharmaceutical firms. The company employs a significant workforce and invests in expanding its portfolio through innovation and strategic partnerships. Positioned as a notable player in the Baltic pharmaceutical sector, Grindeks contributes to the supply of essential medicines in the region while adhering to strict regulatory requirements.
CHMP limits ipidacrine to specific neuropathies, Alzheimer’s, intestinal atony and certain stroke/TBI recovery uses; removes several neuritis and demyelinating indications; cautions >80 mg/day.
